CRISPR Therapeutics AG (CRSP) Non-Current Assets (2015 - 2026)

CRISPR Therapeutics AG has disclosed Non-Current Assets across 12 years of filings, most recently posting $277.5 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $277.5 million, down 7.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 6.09% YoY), and the FY2025 annual result was $279.6 million, down 8.31% from the prior year.
• Non-Current Assets came in at $277.5 million for Q1 2026 at CRISPR Therapeutics AG, down from $279.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $420.7 million in Q3 2022 to a low of $277.5 million in Q1 2026.
• The 5-year median for Non-Current Assets is $321.5 million (2023), against an average of $327.5 million.
• Across the five-year window, Non-Current Assets soared 175.23% in 2022 and declined 22.44% in 2023, its largest moves.
• CRISPR Therapeutics AG's Non-Current Assets stood at $390.0 million in 2022, then decreased by 17.57% to $321.5 million in 2023, then retreated by 5.16% to $304.9 million in 2024, then dropped by 8.31% to $279.6 million in 2025, then dropped by 0.76% to $277.5 million in 2026.
• The last three Non-Current Assets figures came in at $277.5 million (Q1 2026), $279.6 million (Q4 2025), and $316.2 million (Q3 2025), per Business Quant data.